NIH Scientists Demonstrate Genetic Variant is Linked to Greater Effectiveness of Smoking Cessation Medication – September 10, 2007


A genetic variant present in nearly half of Americans of European
ancestry is linked to greater effectiveness of the smoking cessation
medication bupropion (Zyban), according to research by scientists
supported by the National Institute on Drug Abuse (NIDA) and the
National Cancer Institute (NCI), part of the National Institutes
of Health (NIH). People with this variant were less likely than
those without it to have resumed smoking six months after treatment
with bupropion.

Comments are closed.